Lung cancer is the leading cause of cancer death in the U.S. One of the major obstacles in treating lung cancer is its late presentation, when the options for treatment are primarily palliative. The lack of effective therapy underscores the urgency to reevaluate our current management strategy and explore new frontiers of treatment such as chemoprevention in high-risk individuals. Previous studies have shown that former heavy smokers (equal to or > 30 pack years), particularly those with airflow obstruction and/or a history of stage I non-small cell lung cancer (NSCLC) who have had curative resection, continue to have significantly elevated cancer risk than never smokers. Therefore, the overall objective of this pilot proposal is to evaluate the feasibility and effectiveness of Celecoxib, a cyclooxygenase-2 (Cox-2) inhibitor, for lung cancer prevention in this high-risk population. To achieve this objective, 180 former heavy smokers, with either evidence of airflow obstruction and/or prior stage I NSCLC, will be recruited into a double blind, placebo controlled, crossover pilot study. Subjects will be treated in random order with either 6 months of oral Celecoxib as a chemopreventive agent first, followed by 6 months of placebo or vise versa. All subjects will be followed with serial tests including sputum analysis, LIFE bronchoscopy and spiral CT according to a pre- determined algorithm. Celecoxib will be evaluated for its impact on cellular and molecular events associated with lung carcinogenesis: including 1) modulation of a panel of biomarkers of field cancerization (Ki-67, phenotypic modulations of bronchial histopathology, alteration of prostaglandin E2 production in bronchoalveolar lavage fluid, expression of Cox-2, EGFR, p27,p16, bcl-2, apoptosis index, cyclin D1 and E, GSTP1 methylation, GSTP1, GSTM1 and CYP1A1 polymorphisms, P53 polymorphisms and p16 methylation; 2) regulation of arachidonic acid metabolism; 3) antitumor immunity; and 4) angiogenesis in the lung microenvironment. The safety and side effect of long term use of Cox-2 inhibition will be monitored with the modified NCI common toxicity criteria scale and serial adverse reaction questionnaire. Moreover, serial bronchial tissue, sputum, buccal smear, blood (plasma and buffy coat), and urine specimens, respiratory and health questionnaires will be archived for future analysis. The finding from this pilot project will provide important insight into the design and conduct of future chemopreventive trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA096134-04
Application #
6927164
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J3))
Program Officer
Szabo, Eva
Project Start
2002-07-12
Project End
2008-06-30
Budget Start
2005-08-01
Budget End
2006-06-30
Support Year
4
Fiscal Year
2005
Total Cost
$1,051,799
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Zhao, Jin-Kou; Wu, Ming; Kim, Claire H et al. (2017) Jiangsu Four Cancers Study: a large case-control study of lung, liver, stomach, and esophageal cancers in Jiangsu Province, China. Eur J Cancer Prev 26:357-364
Meyers, Travis J; Chang, Shen-Chih; Chang, Po-Yin et al. (2017) Case-control study of cumulative cigarette tar exposure and lung and upper aerodigestive tract cancers. Int J Cancer 140:2040-2050
Kawakita, Daisuke; Lee, Yuan-Chin Amy; Turati, Federica et al. (2017) Dietary fiber intake and head and neck cancer risk: A pooled analysis in the International Head and Neck Cancer Epidemiology consortium. Int J Cancer 141:1811-1821
Boffetta, Paolo; Hayes, Richard B; Sartori, Samantha et al. (2016) Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium. Eur J Cancer Prev 25:344-8
Wyss, Annah B; Hashibe, Mia; Lee, Yuan-Chin Amy et al. (2016) Smokeless Tobacco Use and the Risk of Head and Neck Cancer: Pooled Analysis of US Studies in the INHANCE Consortium. Am J Epidemiol 184:703-716
Leoncini, Emanuele; Edefonti, Valeria; Hashibe, Mia et al. (2016) Carotenoid intake and head and neck cancer: a pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Eur J Epidemiol 31:369-83
Chen, Li-Shiun; Baker, Timothy; Hung, Rayjean J et al. (2016) Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis. EBioMedicine 11:219-226
Hashim, D; Sartori, S; Brennan, P et al. (2016) The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium. Ann Oncol 27:1619-25
Chen, Li-Shiun; Hung, Rayjean J; Baker, Timothy et al. (2015) CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis. J Natl Cancer Inst 107:
Huang, Ruyi; Wei, Yongyue; Hung, Rayjean J et al. (2015) Associated Links Among Smoking, Chronic Obstructive Pulmonary Disease, and Small Cell Lung Cancer: A Pooled Analysis in the International Lung Cancer Consortium. EBioMedicine 2:1677-85

Showing the most recent 10 out of 48 publications